Trials / Completed
CompletedNCT04983888
Obinutuzumab in Primary FSGS
A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Obinutuzumab | 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6 |
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2025-06-16
- Completion
- 2025-06-16
- First posted
- 2021-07-30
- Last updated
- 2025-09-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04983888. Inclusion in this directory is not an endorsement.